Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Int J Mol Sci ; 25(3)2024 Feb 02.
Article in English | MEDLINE | ID: mdl-38339098

ABSTRACT

Diabetes mellitus is clinically defined by chronic hyperglycemia. Sex differences in the presentation and outcome of diabetes exist with premenopausal women having a reduced risk of developing diabetes, relative to men, or women after menopause. Accumulating evidence shows a protective role of estrogens, specifically 17-beta estradiol, in the maintenance of pancreatic beta cell health; however, the mechanisms underlying this protection are still unknown. To elucidate these potential mechanisms, we used a pancreatic beta cell line (BTC6) and a mouse model of hyperglycemia-induced atherosclerosis, the ApoE-/-:Ins2+/Akita mouse, exhibiting sexual dimorphism in glucose regulation. In this study we hypothesize that 17-beta estradiol protects pancreatic beta cells by modulating the unfolded protein response (UPR) in response to endoplasmic reticulum (ER) stress. We observed that ovariectomized female and male ApoE-/-:Ins2+/Akita mice show significantly increased expression of apoptotic UPR markers. Sham operated female and ovariectomized female ApoE-/-:Ins2+/Akita mice supplemented with exogenous 17-beta estradiol increased the expression of adaptive UPR markers compared to non-supplemented ovariectomized female ApoE-/-:Ins2+/Akita mice. These findings were consistent to what was observed in cultured BTC6 cells, suggesting that 17-beta estradiol may protect pancreatic beta cells by repressing the apoptotic UPR and enhancing the adaptive UPR activation in response to pancreatic ER stress.


Subject(s)
Diabetes Mellitus , Hyperglycemia , Insulin-Secreting Cells , Humans , Female , Mice , Male , Animals , Insulin-Secreting Cells/metabolism , Estradiol/pharmacology , Estradiol/metabolism , Unfolded Protein Response , Diabetes Mellitus/metabolism , Endoplasmic Reticulum Stress , Hyperglycemia/metabolism , Apolipoproteins E/metabolism
2.
Int J Mol Sci ; 25(2)2024 Jan 12.
Article in English | MEDLINE | ID: mdl-38256027

ABSTRACT

Sex differences in the development and progression of cardiovascular disease are well established, but the effects of sex hormones on macrophage polarization and pro-atherogenic functions are not well described. We hypothesize that sex hormones directly modulate macrophage polarization, and thereby regulate the progression of atherosclerosis. Bone marrow-derived monocytes from adult male and female C57BL/6 mice were differentiated into macrophages using macrophage colony-stimulating factor (20 ng/mL) and pre-treated with either 17ß-estradiol (100 nM), testosterone (100 nM), or a vehicle control for 24 h. Macrophages were polarized into pro- or anti-inflammatory phenotypes and the effects of sex hormone supplementation on the gene expression of macrophage phenotypic markers were assessed using RT-qPCR. Inflammatory markers, including IL-1ß, were quantified using an addressable laser bead immunoassay. A transwell migration assay was used to determine changes in macrophage migration. Sex differences were observed in macrophage polarization, inflammatory responses, and migration. Pre-treatment with 17ß-estradiol significantly impaired the gene expression of inflammatory markers and the production of IL-1ß in inflammatory macrophages. In anti-inflammatory macrophages, 17ß-estradiol significantly upregulated the expression of anti-inflammatory markers and enhanced migration. Pre-treatment with testosterone enhanced anti-inflammatory mRNA expression and impaired the production of IL-1ß. Our observations suggest a protective role of 17ß-estradiol in atherogenesis that may contribute to the sexual dimorphisms in cardiovascular disease observed in human patients.


Subject(s)
Atherosclerosis , Cardiovascular Diseases , Mice , Adult , Animals , Female , Humans , Male , Mice, Inbred C57BL , Gonadal Steroid Hormones , Estradiol/pharmacology , Testosterone/pharmacology , Interleukin-1beta/genetics , Macrophages , Anti-Inflammatory Agents
3.
Am J Pathol ; 194(4): 551-561, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38061627

ABSTRACT

Diabetes is a prevalent disease, primarily characterized by high blood sugar (hyperglycemia). Significantly higher rates of myocardial dysfunction have been noted in individuals with diabetes, even in those without coronary artery disease or high blood pressure (hypertension). Numerous molecular mechanisms have been identified through which diabetes contributes to the pathology of diabetic cardiomyopathy, which presents as cardiac hypertrophy and fibrosis. At the cellular level, oxidative stress and inflammation in cardiomyocytes are triggered by hyperglycemia. Although males are generally more likely to develop cardiovascular disease than females, diabetic males are less likely to develop diabetic cardiomyopathy than are diabetic females. One reason for these differences may be the higher levels of serum testosterone in males compared with females. Although testosterone appears to protect against cardiomyocyte oxidative stress and exacerbate hypertrophy, its role in inflammation and fibrosis is much less clear. Additional preclinical and clinical studies will be required to delineate testosterone's effect on the diabetic heart.


Subject(s)
Diabetes Mellitus , Diabetic Cardiomyopathies , Hyperglycemia , Hypertension , Humans , Male , Female , Diabetic Cardiomyopathies/drug therapy , Diabetic Cardiomyopathies/pathology , Testosterone/pharmacology , Sex Characteristics , Cardiomegaly , Oxidative Stress , Fibrosis , Inflammation
4.
Int J Mol Sci ; 24(13)2023 Jul 02.
Article in English | MEDLINE | ID: mdl-37446181

ABSTRACT

The endocannabinoid system (ECS) governs and coordinates several physiological processes through an integrated signaling network, which is responsible for inducing appropriate intracellular metabolic signaling cascades in response to (endo)cannabinoid stimulation. This intricate cellular system ensures the proper functioning of the immune, reproductive, and nervous systems and is involved in the regulation of appetite, memory, metabolism, and development. Cannabinoid receptors have been observed on both cellular and mitochondrial membranes in several tissues and are stimulated by various classes of cannabinoids, rendering the ECS highly versatile. In the context of growth and development, emerging evidence suggests a crucial role for the ECS in cellular growth and differentiation. Indeed, cannabinoids have the potential to disrupt key energy-sensing metabolic signaling pathways requiring mitochondrial-ER crosstalk, whose functioning is essential for successful cellular growth and differentiation. This review aims to explore the extent of cannabinoid-induced cellular dysregulation and its implications for cellular differentiation.


Subject(s)
Cannabinoids , Cannabinoids/pharmacology , Cannabinoids/metabolism , Endocannabinoids/metabolism , Receptors, Cannabinoid/metabolism , Signal Transduction , Cell Differentiation
5.
J Exp Clin Cancer Res ; 42(1): 2, 2023 Jan 02.
Article in English | MEDLINE | ID: mdl-36588164

ABSTRACT

BACKGROUND: PCSK9 regulates cholesterol homeostasis and promotes tumorigenesis. However, the relevance of these two actions and the mechanisms underlying PCSK9's oncogenic roles in melanoma and other cancers remain unclear. METHODS: PCSK9's association with melanoma was analysed using the TCGA dataset. Empty vector (EV), PCSK9, gain-of-function (D374Y), and loss-of-function (Q152H) PCSK9 mutant were stably-expressed in murine melanoma B16 cells and studied for impact on B16 cell-derived oncogenesis in vitro and in vivo using syngeneic C57BL/6 and Pcsk9-/- mice. Intratumoral accumulation of cholesterol was determined. RNA-seq was performed on individual tumor types. Differentially-expressed genes (DEGs) were derived from the comparisons of B16 PCSK9, B16 D374Y, or B16 Q152H tumors to B16 EV allografts and analysed for pathway alterations. RESULTS: PCSK9 expression and its network negatively correlated with the survival probability of patients with melanoma. PCSK9 promoted B16 cell proliferation, migration, and growth in soft agar in vitro, formation of tumors in C57BL/6 mice in vivo, and accumulation of intratumoral cholesterol in a manner reflecting its regulation of the low-density lipoprotein receptor (LDLR): Q152H, EV, PCSK9, and D374Y. Tumor-associated T cells, CD8 + T cells, and NK cells were significantly increased in D374Y tumors along with upregulations of multiple immune checkpoints, IFNγ, and 143 genes associated with T cell dysfunction. Overlap of 36 genes between the D374Y DEGs and the PCSK9 DEGs predicted poor prognosis of melanoma and resistance to immune checkpoint blockade (ICB) therapy. CYTH4, DENND1C, AOAH, TBC1D10C, EPSTI1, GIMAP7, and FASL (FAS ligand) were novel predictors of ICB therapy and displayed high level of correlations with multiple immune checkpoints in melanoma and across 30 human cancers. We observed FAS ligand being among the most robust biomarkers of ICB treatment and constructed two novel and effective multigene panels predicting response to ICB therapy. The profiles of allografts produced by B16 EV, PCSK9, D374Y, and Q152H remained comparable in C57BL/6 and Pcsk9-/- mice. CONCLUSIONS: Tumor-derived PCSK9 plays a critical role in melanoma pathogenesis. PCSK9's oncogenic actions are associated with intratumoral cholesterol accumulation. PCSK9 systemically affects the immune system, contributing to melanoma immune evasion. Novel biomarkers derived from the PCSK9-network effectively predicted ICB therapy responses.


Subject(s)
Melanoma, Experimental , Melanoma , Humans , Mice , Animals , Proprotein Convertase 9/genetics , Fas Ligand Protein , Mice, Inbred C57BL , Melanoma/genetics , Melanoma, Experimental/genetics , Melanoma, Experimental/pathology , Cell Adhesion Molecules , Guanine Nucleotide Exchange Factors , GTPase-Activating Proteins
6.
Am J Pathol ; 193(1): 121-133, 2023 01.
Article in English | MEDLINE | ID: mdl-36243046

ABSTRACT

It is well established that patients with diabetes have an increased risk of developing atherosclerotic cardiovascular disease. The earliest detectable sign of atherosclerosis initiation is endothelial cell activation. Activated endothelial cells express adhesion proteins, P-selectin, E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1, which function to recruit monocytes to the subendothelial layer. This study examines the effect of hyperglycemia on endothelial cell activation and the initiation and progression of atherosclerosis. In vitro studies revealed that exposure of human aortic endothelial cells to elevated (30 mmol/L) glucose concentrations significantly increased the expression of P-selectin, E-selectin, and vascular cell adhesion molecule-1. In vivo studies showed that, before lesion development, 5-week-old hyperglycemic ApoE-/-Ins2+/akita mice had significantly increased expression of these adhesion proteins in the aortic sinus and increased macrophage infiltration, compared with normoglycemic ApoE-/- controls. At 25 weeks of age, ApoE-/-Ins2+/akita mice had significantly larger atherosclerotic plaques than ApoE-/- controls (0.022 ± 0.004 versus 0.007± 0.001 mm3; P < 0.05). Similar endothelial activation was observed in heterozygous ApoE+/-Ins2+/akita mice; however, detectable atherosclerotic lesions did not develop in the absence of dyslipidemia. Lowering blood glucose levels (by 55%) using a sodium-glucose cotransporter 2 inhibitor reduced endothelial activation. Together, these findings support a causative role for hyperglycemia in atherogenesis and highlight the importance of blood glucose regulation in preventing atherosclerotic cardiovascular disease.


Subject(s)
Atherosclerosis , Cardiovascular Diseases , Hyperglycemia , Plaque, Atherosclerotic , Humans , Mice , Animals , E-Selectin/metabolism , Vascular Cell Adhesion Molecule-1/metabolism , Endothelial Cells/metabolism , Blood Glucose/metabolism , Cardiovascular Diseases/metabolism , Mice, Knockout , Mice, Inbred C57BL , Atherosclerosis/metabolism , Apolipoproteins E/genetics , Apolipoproteins E/metabolism , Plaque, Atherosclerotic/metabolism , Hyperglycemia/complications
7.
Int J Mol Sci ; 23(23)2022 Nov 26.
Article in English | MEDLINE | ID: mdl-36499109

ABSTRACT

Risk factors for developing cardiovascular disease (CVD) are associated with inflammation and endothelial activation. Activated endothelial cells (ECs) express adhesion proteins that recruit monocytes to the subendothelial layer initiating plaque development. Understanding the mechanism(s) by which ECs increase adhesion protein expression will facilitate the development of therapies aimed at preventing CVD progression and mortality. Glycogen synthase kinase (GSK)3α/ß are constitutively active kinases which have been associated with many cellular pathways regulating cell viability and metabolism. While roles for myeloid GSK3α/ß in the development of atherosclerosis have been established, there is limited knowledge on the potential roles of endothelial GSK3α/ß. With the use of Cre recombinase technology, GSK3α/ß was knocked out of both ECs and macrophages (Tie2Cre GSK3α/ßfl/fl LDLR-/-). A bone marrow transplant was used to replenish GSK3α/ß in the myeloid lineage allowing the assessment of an endothelial-selective GSK3α/ß knockout (BMT Tie2Cre GSK3α/ßfl/fl LDLR-/-). In both models, adhesion protein expression, macrophage recruitment and plaque volume were reduced in GSK3α knockout mice. GSK3ß knockout had no significant effect. Results from this study are the first to suggest a pro-atherogenic role of endothelial GSK3α and support existing evidence for targeting GSK3α in the treatment of atherosclerotic CVD.


Subject(s)
Atherosclerosis , Glycogen Synthase Kinase 3 , Plaque, Atherosclerotic , Animals , Mice , Atherosclerosis/genetics , Atherosclerosis/metabolism , Endothelial Cells/metabolism , Glycogen/metabolism , Mice, Knockout , Plaque, Atherosclerotic/metabolism , Receptors, LDL/genetics , Receptors, LDL/metabolism , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3/metabolism
8.
Front Cardiovasc Med ; 9: 964743, 2022.
Article in English | MEDLINE | ID: mdl-36505380

ABSTRACT

There is growing evidence that sex and gender differences play an important role in risk and pathophysiology of type 2 diabetes (T2D). Men develop T2D earlier than women, even though there is more obesity in young women than men. This difference in T2D prevalence is attenuated after the menopause. However, not all women are equally protected against T2D before the menopause, and gestational diabetes represents an important risk factor for future T2D. Biological mechanisms underlying sex and gender differences on T2D physiopathology are not yet fully understood. Sex hormones affect behavior and biological changes, and can have implications on lifestyle; thus, both sex-specific environmental and biological risk factors interact within a complex network to explain the differences in T2D risk and physiopathology in men and women. In addition, lifetime hormone fluctuations and body changes due to reproductive factors are generally more dramatic in women than men (ovarian cycle, pregnancy, and menopause). Progress in genetic studies and rodent models have significantly advanced our understanding of the biological pathways involved in the physiopathology of T2D. However, evidence of the sex-specific effects on genetic factors involved in T2D is still limited, and this gap of knowledge is even more important when investigating sex-specific differences during the life course. In this narrative review, we will focus on the current state of knowledge on the sex-specific effects of genetic factors associated with T2D over a lifetime, as well as the biological effects of these different hormonal stages on T2D risk. We will also discuss how biological insights from rodent models complement the genetic insights into the sex-dimorphism effects on T2D. Finally, we will suggest future directions to cover the knowledge gaps.

9.
Int J Mol Sci ; 23(16)2022 Aug 18.
Article in English | MEDLINE | ID: mdl-36012557

ABSTRACT

Recent evidence from our laboratory suggests that impeding ER stress-GSK3α/ß signaling attenuates the progression and development of atherosclerosis in mouse model systems. The objective of this study was to determine if the tissue-specific genetic ablation of GSK3α/ß could promote the regression of established atherosclerotic plaques. Five-week-old low-density lipoprotein receptor knockout (Ldlr-/-) mice were fed a high-fat diet for 16 weeks to promote atherosclerotic lesion formation. Mice were then injected with tamoxifen to induce macrophage-specific GSK3α/ß deletion, and switched to standard diet for 12 weeks. All mice were sacrificed at 33 weeks of age and atherosclerosis was quantified and characterized. Female mice with induced macrophage-specific GSK3α deficiency, but not GSK3ß deficiency, had reduced plaque volume (~25%) and necrosis (~40%) in the aortic sinus, compared to baseline mice. Atherosclerosis was also significantly reduced (~60%) in the descending aorta. Macrophage-specific GSK3α-deficient mice showed indications of increased plaque stability and reduced inflammation in plaques, as well as increased CCR7 and ABCA1 expression in lesional macrophages, consistent with regressive plaques. These results suggest that GSK3α ablation promotes atherosclerotic plaque regression and identify GSK3α as a potential target for the development of new therapies to treat existing atherosclerotic lesions in patients with cardiovascular disease.


Subject(s)
Atherosclerosis , Glycogen Synthase Kinase 3 , Plaque, Atherosclerotic , Animals , Aorta/metabolism , Atherosclerosis/metabolism , Diet, High-Fat/adverse effects , Disease Models, Animal , Female , Gene Deletion , Glycogen Synthase Kinase 3/genetics , Macrophages/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Plaque, Atherosclerotic/pathology , Protein Serine-Threonine Kinases , Receptors, LDL/metabolism
10.
Am J Physiol Endocrinol Metab ; 323(3): E254-E266, 2022 09 01.
Article in English | MEDLINE | ID: mdl-35830687

ABSTRACT

Sex differences in the prevalence and development of diabetes and associated cardiometabolic complications are well established. The objective of this study was to analyze the effects of estrogen on the maintenance of ß-cell health/function and atherosclerosis progression, using a mouse model of hyperglycemia-induced atherosclerosis, the ApoE-/-:Ins2+/Akita mouse. ApoE-/-:Ins2+/Akita mice exhibit sexual dimorphism in the control of blood glucose levels. Male ApoE-/-:Ins2+/Akita mice are chronically hyperglycemic due to a significant reduction in pancreatic ß-cell mass. Female mice are only transiently hyperglycemic, maintain ß-cell mass, and blood glucose levels normalize at 35 ± 1 days of age. To determine the effects of estrogen on pancreatic ß-cell health and function, ovariectomies and estrogen supplementation experiments were performed, and pancreatic health and atherosclerosis were assessed at various time points. Ovariectomized ApoE-/-:Ins2+/Akita mice developed chronic hyperglycemia with significantly reduced ß-cell mass. To determine whether the observed effects on ovariectomized ApoE-/-:Ins2+/Akita mice were due to a lack of estrogens, slow-releasing estradiol pellets were inserted subcutaneously. Ovariectomized ApoE-/-:Ins2+/Akita mice treated with exogenous estradiol showed normalized blood glucose levels and maintained ß-cell mass. Exogenous estradiol significantly reduced atherosclerosis in both ovariectomized female and male ApoE-/-:Ins2+/Akita mice relative to controls. Together, these findings suggest that estradiol confers significant protection to pancreatic ß-cell health and can directly and indirectly slow the progression of atherosclerosis.NEW & NOTEWORTHY This study examines the effect(s) of estrogen on ß cell and cardiometabolic health/function in a novel mouse model of hyperglycemia-induced atherosclerosis (ApoE-/-:Ins2+/Akita). Using a combination of estrogen deprivation (ovariectomy) and supplementation strategies, we quantify effects on glucose homeostasis and atherogenesis. Our results clearly show a protective role for estrogen on pancreatic ß-cell health and function and glucose homeostasis. Furthermore, estrogen supplementation dramatically reduces atherosclerosis progression in both male and female mice.


Subject(s)
Atherosclerosis , Estrogens , Hyperglycemia , Animals , Atherosclerosis/diagnosis , Atherosclerosis/etiology , Blood Glucose , Disease Models, Animal , Estradiol/pharmacology , Estrogens/pharmacology , Female , Hyperglycemia/complications , Insulin/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout, ApoE
12.
CJC Open ; 3(10): 1238-1248, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34888506

ABSTRACT

Cardiovascular disease (CVD) is the leading cause of death worldwide. The effects of testosterone, the primary male sex hormone, on cardiovascular risk have been of special interest due to the increased risk of CVD in men. Although it is well established that testosterone levels decline and cardiovascular mortality increases with age, the association between testosterone and CVD remains unclear. Observational and randomized studies on the effects of endogenous and exogenous testosterone have produced conflicting data, and meta-analyses have been inconclusive, suggesting significant study heterogeneity. Despite a lack of adequately powered randomized controlled trials, large observational studies in the early 2010s led to advisories on the use of testosterone replacement therapy. Similar advisories have been mandated for certain types of androgen deprivation therapy. Additional research suggests that testosterone shortens the heart-rate-corrected QT interval, improves glycemic control, induces vasodilation, is prothrombotic, and has anti-obesity effects, whereas associations with atherosclerosis and inflammation are less clear. Despite inconclusive evidence on cardiovascular risk and inconsistencies among clinical practice guidelines, millions of men continue to use testosterone replacement and androgen deprivation therapy. In addition to summarizing clinical and preclinical data, this review provides insight on potential mechanisms of action of testosterone on CVD, applications of this knowledge to clinical settings, and avenues for future research.


Les maladies cardiovasculaires (MCV) sont la principale cause de décès dans le monde. Les effets de la testostérone, principale hormone sexuelle masculine, sur le risque cardiovasculaire ont suscité un intérêt particulier en raison du risque accru de MCV chez les hommes. S'il est bien établi que le taux de testostérone diminue et que la mortalité cardiovasculaire augmente avec l'âge, l'association entre la testostérone et les MCV demeure obscure. Les études d'observation et à répartition aléatoire sur les effets de la testostérone endogène et exogène ont donné des données contradictoires, et les méta-analyses n'ont pas été concluantes, laissant entrevoir une hétérogénéité importante des études. Malgré un manque d'essais comparatifs à répartition aléatoire, de vastes études d'observation réalisées au début des années 2010 ont conduit à formuler des avis sur l'utilisation du traitement de substitution de la testostérone. Des avis similaires ont été demandés pour certains types de traitements antiandrogéniques. D'après d'autres recherches, la testostérone raccourcirait l'intervalle QT corrigé en fonction de la fréquence cardiaque, améliorerait la maîtrise glycémique, provoquerait une vasodilatation, exercerait un effet prothrombotique et aurait des effets anti-obésité; en revanche, le lien avec l'athérosclérose et l'inflammation est moins claire. Malgré des preuves peu concluantes sur le risque cardiovasculaire et des incohérences quant aux directives de pratique clinique, des millions d'hommes continuent de recourir à des traitements de substitution de la testostérone et antiandrogéniques. En plus de résumer les données cliniques et précliniques, cette analyse donne un aperçu des modes d'action potentiels de la testostérone sur les MCV, des applications de ces connaissances en contexte clinique et des pistes de recherches futures.

13.
Mol Metab ; 53: 101321, 2021 11.
Article in English | MEDLINE | ID: mdl-34425254

ABSTRACT

OBJECTIVE: Salsalate is a prodrug of salicylate that lowers blood glucose in people with type 2 diabetes. AMP-activated protein kinase (AMPK) is an αßγ heterotrimer which inhibits macrophage inflammation and the synthesis of fatty acids and cholesterol in the liver through phosphorylation of acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HMGCR), respectively. Salicylate binds to and activates AMPKß1-containing heterotrimers that are highly expressed in both macrophages and liver, but the potential importance of AMPK and ability of salsalate to reduce atherosclerosis have not been evaluated. METHODS: ApoE-/- and LDLr-/- mice with or without (-/-) germline or bone marrow AMPKß1, respectively, were treated with salsalate, and atherosclerotic plaque size was evaluated in serial sections of the aortic root. Studies examining the effects of salicylate on markers of inflammation, fatty acid and cholesterol synthesis and proliferation were conducted in bone marrow-derived macrophages (BMDMs) from wild-type mice or mice lacking AMPKß1 or the key AMPK-inhibitory phosphorylation sites on ACC (ACC knock-in (KI)-ACC KI) or HMGCR (HMGCR-KI). RESULTS: Salsalate reduced atherosclerotic plaques in the aortic roots of ApoE-/- mice, but not ApoE-/- AMPKß1-/- mice. Similarly, salsalate reduced atherosclerosis in LDLr-/- mice receiving wild-type but not AMPKß1-/- bone marrow. Reductions in atherosclerosis by salsalate were associated with reduced macrophage proliferation, reduced plaque lipid content and reduced serum cholesterol. In BMDMs, this suppression of proliferation by salicylate required phosphorylation of HMGCR and the suppression of cholesterol synthesis. CONCLUSIONS: These data indicate that salsalate suppresses macrophage proliferation and atherosclerosis through an AMPKß1-dependent pathway, which may involve HMGCR phosphorylation and cholesterol synthesis. Since rapidly-proliferating macrophages are a hallmark of atherosclerosis, these data indicate further evaluation of salsalate as a potential therapeutic agent for treating atherosclerotic cardiovascular disease.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Atherosclerosis/metabolism , Salicylates/metabolism , AMP-Activated Protein Kinases/deficiency , Animals , Cells, Cultured , Mice , Mice, Knockout
14.
Front Immunol ; 12: 676752, 2021.
Article in English | MEDLINE | ID: mdl-34394077

ABSTRACT

The molecular and cellular mechanisms that link cardiovascular risk factors to the initiation and progression of atherosclerosis are not understood. Recent findings from our laboratory indicate that endoplasmic reticulum (ER) stress signaling through glycogen synthase kinase (GSK)-3α/ß induces pro-atherosclerotic pathways. The objective of this study was to define the specific roles of GSK3α and GSK3ß in the activation of pro-atherogenic processes in macrophages. Bone marrow derived macrophages (BMDM) were isolated from low-density lipoprotein receptor knockout (Ldlr-/-) mice and Ldlr-/- mice with myeloid deficiency of GSK3α and/or GSK3ß. M1 and M2 macrophages were used to examine functions relevant to the development of atherosclerosis, including polarization, inflammatory response, cell viability, lipid accumulation, migration, and metabolism. GSK3α deficiency impairs M1 macrophage polarization, and reduces the inflammatory response and lipid accumulation, but increases macrophage mobility/migration. GSK3ß deficiency promotes M1 macrophage polarization, which further increases the inflammatory response and lipid accumulation, but decreases macrophage migration. Macrophages deficient in both GSK3α and GSK3ß exhibit increased cell viability, proliferation, and metabolism. These studies begin to delineate the specific roles of GSK3α and GSK3ß in macrophage polarization and function. These data suggest that myeloid cell GSK3α signaling regulates M1 macrophage polarization and pro-atherogenic functions to promote atherosclerosis development.


Subject(s)
Atherosclerosis/immunology , Cell Polarity/genetics , Glycogen Synthase Kinase 3 beta/metabolism , Glycogen Synthase Kinase 3/metabolism , Macrophages/immunology , Receptors, LDL/genetics , Signal Transduction/genetics , Animals , Atherosclerosis/genetics , Atherosclerosis/metabolism , Cell Movement/genetics , Cell Proliferation/genetics , Cell Survival/genetics , Cells, Cultured , Disease Models, Animal , Gene Knockout Techniques , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3 beta/genetics , Inflammation/genetics , Inflammation/immunology , Inflammation/metabolism , Macrophages/classification , Macrophages/metabolism , Mice , Mice, Knockout
15.
Am J Pathol ; 191(9): 1490-1498, 2021 09.
Article in English | MEDLINE | ID: mdl-34102108

ABSTRACT

Insulin resistance results when peripheral tissues, including adipose, skeletal muscle, and liver, do not respond appropriately to insulin, causing the ineffective uptake of glucose. This represents a risk factor for the development of type 2 diabetes mellitus. Along with abdominal obesity, hypertension, high levels of triglycerides, and low levels of high-density lipoproteins, insulin resistance is a component of a condition known as the metabolic syndrome, which significantly increases the risk of developing cardiometabolic disorders. Accumulating evidence shows that biological sex has a major influence in the development of cardiometabolic disturbances, with females being more protected than males. This protection appears to be driven by female sex hormones (estrogens), as it tends to disappear with the onset of menopause but can be re-established with hormone replacement therapy. This review evaluates current knowledge on the protective role of estrogens in the relevant pathways associated with insulin resistance. The importance of increasing our understanding of sex as a biological variable in cardiometabolic research to promote the development of more effective preventative strategies is emphasized.


Subject(s)
Estrogens/metabolism , Insulin Resistance/physiology , Sex Characteristics , Animals , Female , Humans , Risk Factors
16.
Int J Mol Sci ; 22(4)2021 Feb 23.
Article in English | MEDLINE | ID: mdl-33672232

ABSTRACT

Macrophages are present in nearly all vertebrate tissues, where they respond to a complex variety of regulatory signals to coordinate immune functions involved in tissue development, metabolism, homeostasis, and repair. Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed protein kinase that plays important roles in multiple pathways involved in cell metabolism. Dysregulation of GSK3 has been implicated in several prevalent metabolic disorders, and recent findings have highlighted the importance of GSK3 activity in the regulation of macrophages, especially with respect to the initiation of specific pathologies. This makes GSK3 a potential therapeutic target for the development of novel drugs to modulate immunometabolic responses. Here, we summarize recent findings that have contributed to our understanding of how GSK3 regulates macrophage function, and we discuss the role of GSK3 in the development of metabolic disorders and diseases.


Subject(s)
Glycogen Synthase Kinase 3/physiology , Inflammation/pathology , Macrophages/physiology , Animals , Apoptosis/physiology , Humans , Inflammation/metabolism , Lipid Metabolism , Unfolded Protein Response/physiology
17.
Prostate Cancer Prostatic Dis ; 24(2): 389-397, 2021 06.
Article in English | MEDLINE | ID: mdl-32989260

ABSTRACT

BACKGROUND: Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, a population with high prevalence of cardiovascular disease and its risk factors. Our objectives were to test and further characterize the effects of pharmacological castration which is currently the acceptable modality to deliver ADT in the clinic. METHODS: Male ApoE-/-:Ins2+/Akita mice received one of three modes of ADT (gonadotropin-releasing hormone (GnRH)-antagonist (degarelix), GnRH-agonist (leuprolide), or bilateral orchiectomy) and were compared to corresponding untreated control mice (n = 9-13/group). Mice were followed for 5 months. Body weight, fasting blood glucose, glucose tolerance, serum C-peptide, leptin, and testosterone levels along with atherosclerotic aortic plaque size and characteristics were determined. In a separate experiment, the survival of mice, untreated and on ADT, was determined. RESULTS: Castration was achieved for all three modes of ADT. However, degarelix-treated mice gained significantly less weight, had lower serum leptin levels and systolic blood pressure compared to orchiectomy and leuprolide-treated mice. ADT improved dysglycemia and atherosclerotic burden. GnRH-antagonist significantly improved survival compared to GnRH-agonist but not compared to orchiectomy. CONCLUSIONS: Further characterization of the ApoE-/-:Ins2+/Akita mouse model confirms that pharmacological ADT ameliorated metabolic syndrome and cardiovascular complications. Improved dysglycemia and atherosclerosis associated with increased survival which was longest after degarelix followed by orchiectomy.


Subject(s)
Androgen Antagonists/pharmacology , Cardiovascular Diseases/prevention & control , Disease Models, Animal , Hyperglycemia/complications , Metabolic Syndrome/prevention & control , Orchiectomy/methods , Protective Factors , Animals , Antineoplastic Agents, Hormonal/pharmacology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/pathology , Insulin/physiology , Leuprolide/pharmacology , Male , Metabolic Syndrome/etiology , Metabolic Syndrome/pathology , Mice , Mice, Knockout, ApoE/physiology , Oligopeptides/pharmacology
18.
Invest Ophthalmol Vis Sci ; 61(10): 49, 2020 08 03.
Article in English | MEDLINE | ID: mdl-32852545

ABSTRACT

Purpose: Recent evidence suggests that there is a correlation between the micro- and macrovascular complications of diabetes mellitus. The aim of this study is to investigate the molecular mechanisms by which diabetes promotes the development of microvascular disease (diabetic retinopathy [DR]) through characterization of the effects of hyperglycemia in the retina of mouse models of diabetic atherosclerosis. Methods: Hyperglycemia was induced in apolipoprotein E-deficient (ApoE-/-) mice, a model of accelerated atherosclerosis, either through streptozotocin (STZ) injection or introduction of the Ins2Akita mutation (ApoE-/-Ins2+/Akita). Another subset of ApoE-/- mice was supplemented with glucosamine (GlcN). To attenuate atherosclerosis, subsets of mice from each experimental group were treated with the chemical chaperone, 4-phenylbutyric acid (4PBA). Eyes from 15-week-old mice were either trypsin digested and stained with periodic acid-Schiff (PAS) or frozen for cryostat sectioning and immunostained for endoplasmic reticulum (ER) stress markers, including C/EBP homologous protein (CHOP) and 78-kDa glucose-regulated protein (GRP78). PAS-stained retinal flatmounts were analyzed for microvessel density, acellular capillaries, and pericyte ghosts. Results: Features of DR, including pericyte ghosts and reduced microvessel density, were observed in hyperglycemic and GlcN-supplemented mice. Treatment with 4PBA reduced ER stress in the retinal periphery and attenuated DR in the experimental groups. Conclusions: Mouse models of diabetic atherosclerosis show characteristic pathologies of DR that correlate with atherosclerosis. The increased magnitude of these changes and responses to 4PBA in the peripheral retina suggest that future studies should be aimed at assessing regional differences in mechanisms of ER stress-related pathways in these mouse models.


Subject(s)
Atherosclerosis/etiology , Diabetic Angiopathies/pathology , Diabetic Retinopathy/etiology , Endoplasmic Reticulum Stress , Animals , Apolipoproteins E/metabolism , Atherosclerosis/pathology , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/pathology , Diabetic Angiopathies/complications , Diabetic Retinopathy/pathology , Disease Models, Animal , Endoplasmic Reticulum Chaperone BiP , Female , Fluorescent Antibody Technique , Hyperglycemia/complications , Hyperglycemia/pathology , Male , Mice , Mice, Knockout , Microvessels/pathology , Retinal Vessels/pathology
19.
Can J Diabetes ; 44(5): 448-452, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32127295

ABSTRACT

The incidence and prevalence of diabetes mellitus, and the cardiovascular complications associated with this disease, are rapidly increasing worldwide. Individuals with diabetes have a higher mortality rate due to cardiovascular diseases and a reduced life expectancy compared to those without diabetes. This poses a significant economic burden on health-care systems worldwide, making the diabetes epidemic a global health crisis. Sex differences in the presentation and outcome of diabetes do exist. Premenopausal women are protected from developing diabetes and its cardiovascular complications relative to males and postmenopausal women. However, women with diabetes tend to have a higher mortality as a result of cardiovascular complications than age-matched men. Despite this evidence, preclinical and clinical research looking at sex as a biologic variable in metabolic disorders and their cardiovascular complications is very limited. The aim of this review is to highlight the current knowledge of the potential protective role of estrogens in humans as well as rodent models of diabetes mellitus, and the possible pathways by which this protection is conferred. We stress the importance of increasing knowledge of sex-specific differences to facilitate the development of more targeted prevention strategies.


Subject(s)
Diabetes Complications/metabolism , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 2/metabolism , Estrogens/metabolism , Animals , Disease Models, Animal , Humans , Insulin Secretion , Insulin-Secreting Cells/metabolism , Mice , Postmenopause , Premenopause , Protective Factors , Rats , Receptors, Estrogen/metabolism , Risk Factors , Sex Characteristics , Sex Factors
20.
Diabetes Care ; 42(5): 980-982, 2019 05.
Article in English | MEDLINE | ID: mdl-30862652

ABSTRACT

OBJECTIVE: This study was conducted to determine the relationship between dysglycemia and the coronary artery vasa vasorum density. RESEARCH DESIGN AND METHODS: The left anterior descending coronary artery was removed from 57 deceased individuals during autopsy, and the capillaries in the vessel wall were identified using fluorescent immunohistochemical staining. HbA1c was determined in postmortem whole blood for each individual. The density of the vasa vasorum in the intima-media and the adventitia was manually quantified and recorded by readers unaware of the individual's other characteristics. RESULTS: The individuals with diabetes had a lower density of the coronary vasa vasorum than those without diabetes. The higher the HbA1c, the lower the density of these vessels in the adventitia and entire vessel wall. CONCLUSIONS: Dysglycemia-induced damage to the vasa vasorum may promote ischemic heart disease in people with diabetes.


Subject(s)
Coronary Vessels/pathology , Glucose Metabolism Disorders/pathology , Vasa Vasorum/pathology , Aged , Aged, 80 and over , Animals , Autopsy , Blood Glucose/metabolism , Cell Count , Coronary Artery Disease/blood , Coronary Artery Disease/pathology , Female , Glucose Metabolism Disorders/blood , Glycated Hemoglobin/analysis , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Myocardial Ischemia/blood , Myocardial Ischemia/pathology , Tunica Intima/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...